Abstract

Acute Respiratory Infections (ARIs) are responsible for considerable morbidity and mortality worldwide. Documentation of respiratory specimens can help for an appropriate clinical management with a significant effect on the disease progress in patient, the antimicrobial therapy used and the risk of secondary spread of infection. Here, we compared the performances of four commercial multiplex kits used in French University Hospital diagnostic microbiology laboratories for the detection of ARI pathogens (i.e., the xTAG Respiratory Viral Panel Fast, RespiFinder SMART 22, CLART PneumoVir and Fast Track Diagnostics Respiratory Pathogen 33 kits). We used a standardised nucleic acids extraction protocol and a comprehensive comparative approach that mixed reference to well established real-time PCR detection techniques and analysis of convergent positive results. We tested 166 respiratory clinical samples and identified a global high degree of correlation for at least three of the techniques (xTAG, RespiFinder and FTD33). For these techniques, the highest Youden’s index (YI), positive predictive (PPV) and specificity (Sp) values were observed for Core tests (e.g., influenza A [YI:0.86–1.00; PPV:78.95–100.00; Sp:97.32–100.00] & B [YI:0.44–1.00; PPV:100.00; Sp:100.00], hRSV [YI:0.50–0.99; PPV:85.71–100.00; Sp:99.38–100.00], hMPV [YI:0.71–1.00; PPV:83.33–100.00; Sp:99.37–100.00], EV/hRV [YI:0.62–0.82; PPV:93.33–100.00; Sp:94.48–100.00], AdV [YI:1.00; PPV:100.00; Sp:100.00] and hBoV [YI:0.20–0.80; PPV:57.14–100.00; Sp:98.14–100.00]). The present study completed an overview of the multiplex techniques available for the diagnosis of acute respiratory infections.

Highlights

  • Acute Respiratory Infections (ARIs) are responsible for considerable morbidity and mortality worldwide [1]

  • It was under 80% for the PneumoVir and FTD-RP33 kits and under 50% for the xTagRVP-F kit

  • Previous studies included comparison with other multiplex commercial kits: xTAG Respiratory Viral Panel Fast assay versus FilmArray respiratory viral panel, ResPlex II Panel v2.0, MultiCode-PLx, Seeplex RV15 OneStep ACE Detection and Pneumobacter ACE Detection and xTAG Respiratory Viral Panel v1 kits [7,23,25]; RespiFinder SMART 22 assay versus Seeplex RV15 OneStep ACE Detection and Pneumobacter ACE Detection, ResPlex II Panel v2.0, RespiFinder 19 kits [2,9,26,27]; Fast Track Diagnostics Respiratory Pathogen 21 versus xTAG Respiratory Viral Panel fast and Easyplex respiratory pathogen 12 kits [16]

Read more

Summary

Introduction

Acute Respiratory Infections (ARIs) are responsible for considerable morbidity and mortality worldwide [1]. Multiplex molecular detection tests have been increasingly developed in recent years and a number of commercial kits have been proposed to diagnostic microbiology laboratories, which allow the detection of 12 to 33 different pathogens This includes the xTAG Respiratory Viral Panel, Fast or v1, assays (Luminex Molecular Diagnostics, Toronto, Canada); the FilmArray respiratory viral panel assay (BioFire Diagnostics, Salt Lake City, UT); the Fast Track Diagnostics Respiratory Pathogen, 21 or 33, assays (Fast Track Diagnostics, Luxembourg); the CLART PneumoVir (Genomica, Coslada, Spain); the RespiFinder, 19 or SMART 22, assay (Pathofinder, Maastricht, Netherlands); the eSensor Respiratory Viral Panel (GenMark Dx, Carlsbad, CA); the MultiCode-PLx (EraGen Biosciences); the Easyplex respiratory pathogen 12 kit (Ausdiagnostics, Sydney, Australia); the Seeplex RV15 OneStep ACE Detection and Pneumobacter ACE Detection (Seegene Inc., Seoul, South Korea); the Magicplex RV Panel Real-time Test (Seegene Inc); and the ResPlex II Panel v2.0 (Qiagen, Hilden, Germany). Direct comparison of commercialised multiplex kits was undertaken, with reference to in-house multiplex real-time PCR systems [16], or to commercial duplex PCR tests [17]

Methods
Results
Discussion
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.